The Architecture of Translation
We do not rely on empirical guesswork. Our methodology fuses deep medical foresight with mathematical precision to engineer a definitive pathway from bench to clinic.
01. In Silico Interrogation
Before physical formulation begins, we aggressively interrogate the molecule’s physical limitations. Utilising the secure SynapTx™ AI ecosystem, we mathematically model multivariable excipient interactions, predict solubility walls, and anticipate pharmacokinetic bottlenecks. By simulating the asset’s behaviour computationally, we eliminate weeks of costly bench-level trial and error, establishing a highly referenced, data-backed foundation for the project.
02. Precision Bench Execution
Armed with predictive models, we transition to the physical laboratory. We engineer sophisticated solid-state architectures and advanced delivery mechanisms tailored precisely to the molecule’s unique biological barriers. Every physical iteration is deeply governed by In Vitro-In Vivo Correlation (IVIVC) principles. We do not just solve for solubility; we engineer the dosage form to strictly control pharmacokinetic exposure and maximise human clinical efficacy.
03. Strategic Industrialisation
A flawless preclinical asset is useless if it cannot be industrialised. We protect your investment by acting as your dedicated scientific proxy during the scale-up phase. We architect stringent Chemistry, Manufacturing, and Controls (CMC) protocols and drive the technology transfer to your chosen manufacturing partners. By maintaining uncompromising technical stewardship on the manufacturing floor, we guarantee strict ICH compliance and definitive regulatory certainty.